ReviewMedical oncology (Northwood, London, England)2025
The role of Wnt/β-catenin signaling in lung cancer progression and therapy: a comprehensive review.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GRP78 Drives NSCLC Stemness and EMT via a SIX1/β-Catenin Signaling Axis.Drug development research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most instances of lung cancer (LC), which is the primary cause of cancer-related death worldwide, are non-small-cell lung cancer (NSCLC). Genetic predispositions, environmental exposures, and smoking are risk factors that lead to the development of LC, and the ineffectiveness of existing treatments emphasizes the need for innovative approaches to therapy. Through its regulation of cell proliferation, apoptosis, epithelial-to-mesenchymal transition (EMT), and cancer stem cell maintenance, the Wnt/β-catenin signaling system is essential to advancing LC. This study offers a thorough examination of Wnt/β-catenin signaling in LC, emphasizing how miRNAs, long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), protein-coding genes, enzymes, and both natural and synthetic drugs affect this signaling. Recent research supports the dual function of Wnt/β-catenin signaling in tumor development and repression, which we describe. We also emphasize the therapeutic potential of Wnt/β-catenin inhibitors despite issues including off-target effects and bioavailability. This study highlights the potential of focusing on Wnt/β-catenin signaling to enhance LC patient outcomes by combining computational studies with molecular insights. It also lays the groundwork for further research and treatment development.
Indexed as
Identifiers
40289194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.